CalciMedica returns to profit in Q1 FY26, posts $4.98 million net income

• CalciMedica swung to net income of USD 4.98 million, versus a net loss of USD 5.04 million a year earlier.
• Operating loss narrowed 14% to USD 5.61 million, while total operating expenses fell 14% to USD 5.61 million.
• Research and development expense dropped 17% to USD 3.49 million, due primarily to lower preclinical and clinical trial activities and chemistry, manufacturing and controls costs.
• Other income rose to USD 10.59 million from USD 1.46 million, driven by higher non-cash gains from fair value adjustments to warrant liabilities and a promissory note.
• Cash and cash equivalents totaled USD 8.2 million; company expects cash to fund current operating plan into fourth-quarter 2026 and paused enrollment in KOURAGE Phase 2 trial of Auxora in AKI with AHRF following an IDMC recommendation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-219426), on May 12, 2026, and is solely responsible for the information contained therein.